Printer Friendly

BIOSOURCE GENETICS ANNOUNCES NON-EXCLUSIVE AGREEMENT

 BIOSOURCE GENETICS ANNOUNCES NON-EXCLUSIVE AGREEMENT
 VACAVILLE, Calif., Nov. 22 /PRNewswire/ -- Biosource Genetics


Corporation, the world's largest manufacturer of melanin, announced today a licensing and supply agreement with Advanced Polymer Systems, Inc. (NASDAQ: APOS) (APS), Redwood City, Calif., under which Biosource grants APS nonexclusive worldwide rights to use and sell Biosource's genetically engineered melanin for incorporation into Microsponge(TM) APS products. The first APS product to incorporate Biosource-developed melanin, Prozone, is designed to provide broad spectrum protection against harmful UVA and UVB rays.
 The broad uses of Biosource's genetically engineered melanin range from sun protectant products and natural hair dyes to selected therapeutic indications. Biosource fully intends to commercialize these applications with strategic partners.
 Biosource Genetics has also developed GENEWARE(TM) system, a major technological advance that gives selected plants the ability to make specialty complex biochemicals. With the GENEWARE(TM) system, it is now possible to use a single technology to produce products that cannot be economically made by other means. Biosource is currently in negotiations with major U.S. companies to license the broad range of uses of this technology.
 Biosource Genetics Corporation is located at 3333 Vaca Valley Parkway in Vacaville, Calif.
 -0- 11/22/91
 /CONTACT: John Rakitan, vice president administration, of Biosource Genetics, 707-446-5501/ (APOS) CO: Biosource Genetics Corporation, Advanced Polymer Systems, Inc. ST: California IN: MTC SU: JVN


LC -- CL013 -- 6523 11/22/91 16:33 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1991
Words:232
Previous Article:OKC LIMITED PARTNERSHIP ANNOUNCED CASH DISTRIBUTION
Next Article:FLORIDA REGIONAL STOCK REPORT FOR FRIDAY, NOV. 22
Topics:


Related Articles
TRANSKARYOTIC THERAPIES AND GENETICS INSTITUTE COLLABORATE ON COMMERCIALIZATION OF GENE THERAPY PRODUCT FOR HEMOPHILIA A
BIOSOURCE GENETICS AND NEW ENGLAND MEDICAL CENTER ANNOUNCE RESEARCH AGREEMENT
BIOSOURCE INTERNATIONAL ANNOUNCES LICENSING OF ANTIBODY CELL LINES
TARGETED GENETICS LICENSES IN VIVO AAV TECHNOLOGIES FOR HUMAN GENE THERAPY
Lexicon Genetics Grants Roche Bioscience Renewal to Technology Sublicense.
Lexicon Genetics Licenses Patented Gene Targeting Technology To Merck & Co., Inc.
Lexicon Genetics licenses patented gene targeting technology.
Genzyme Genetics licenses colon cancer diagnostic.
Lexicon Genetics grants license to AstraZeneca.
Roche renews internal research license for patented gene targeting technology from Lexicon.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters